Related Experiment Video
Updated: Dec 24, 2025
Brain Ventricular Microinjections of Lipopolysaccharide into Larval Zebrafish to Assess Neuroinflammation and Neurotoxicity
Published on: August 23, 2022
Malvidin prevents lipopolysaccharide-induced oxidative stress and inflammation in human peripheral blood mononuclear
Ali R Bastin1, Asie Sadeghi1, Moslem Abolhassani1
1Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Abstract:
It is indicated that malvidin has anti-inflammatory and antioxidant effects on various cells, although the function of malvidin in preventing inflammatory reactions caused by lipopolysaccharide (LPS) in peripheral blood mononuclear cells (PBMCs) is still not known. The objective of this study was to examine the impact of malvidin on inflammatory responses and oxidative stress in PBMCs as caused by LPS. The present findings showed that LPS significantly increased the expression of IL-6, TNF-α, IL-1β, and COX-2 mRNA and protein release from PBMCs 22 hr after treatments. It was also revealed that increased levels in cytokine expression coincided with increased phosphorylation of JNK, P65-NF-κB, and IKKα/IKKβ. Also, the expression of IL-6, TNF-α, IL-1β, and COX-2 mRNA induced by LPS as well as secretion of protein in PBMC has been significantly decreased by pretreatment of malvidin. Importantly, pretreatment of the cells with malvidin completely abrogated the phosphorylation of P65-NF-κB, JNK, and IKKα/IKKβ in LPS treated cells. Malvidin protection against LPS-induced inflammation was coupled with a decline in the levels of nitric oxide metabolite and malondialdehyde, along with an increase in the ferric reducing antioxidant power, total thiol activity, and also superoxide dismutase and glutathione peroxidase activity. In accordance with this finding, malvidin may represent a promising therapeutic agent for the prevention of inflammation in PBMCs.
Insights
Malvidin effectively reduces inflammation and oxidative stress in human immune cells. This study shows malvidin pretreatment prevents lipopolysaccharide-induced inflammatory responses in peripheral blood mononuclear cells (PBMCs).
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Malvidin is known for anti-inflammatory and antioxidant properties.
- Its role in preventing lipopolysaccharide (LPS)-induced inflammation in peripheral blood mononuclear cells (PBMCs) remains uncharacterized.
Purpose of the Study:
- To investigate the effect of malvidin on LPS-induced inflammatory responses and oxidative stress in PBMCs.
- To elucidate the underlying molecular mechanisms of malvidin's action.
Main Methods:
- PBMCs were treated with LPS, with or without malvidin pretreatment.
- Analysis of inflammatory markers (IL-6, TNF-α, IL-1β, COX-2), signaling pathways (JNK, P65-NF-κB, IKKα/IKKβ), and oxidative stress indicators (nitric oxide, malondialdehyde, antioxidant power, thiol activity, SOD, GPx).
Main Results:
- LPS significantly upregulated inflammatory markers and key signaling pathway phosphorylation.
- Malvidin pretreatment markedly decreased LPS-induced inflammation and signaling pathway activation.
- Malvidin treatment restored antioxidant capacity and reduced oxidative stress markers.
Conclusions:
- Malvidin demonstrates significant protective effects against LPS-induced inflammation and oxidative stress in PBMCs.
- Malvidin may serve as a potential therapeutic agent for preventing inflammatory conditions.
